Exscientia plc (EXAI) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Oxford, 영국. 현재 CEO는 David Hallett.
EXAI 을(를) 보유 IPO 날짜 2021-10-01, 483 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $633.18M.
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
